Experiences with fibrinolysin in peripheral vascular occlusive disease

The purpose of this paper is to present our experience with fibrinolysin (Thrombolysin) in the treatment of twenty-three patients with thromboembolic disease. The historic background of the use of fibrinolytic agents and the biochemical derivation of the preparation used have been described previously. We agree completely with a recent editorial setting down the requirements for an ideal thrombolytic agent. The present study was initiated with a note of pessimism, since previous proteolytic enzymes administered by various routes had dismally failed in our experience.